| SciPort RLP

2021 - 2024

DFG: CKAMP59: an AMPA or GABA receptor auxiliary subunit?

Univ.-Prof. Dr. Jakob

2021 - 2026

PhaseII/III study comparing trabectedin (T) versus T plus tTF-NGR to entrap T inside the tumor in patients with metastatic and/or refractory soft tissue sarcoma (STS, 2nd line)

Thomas,
Marius

2021 - 2024

Bedeutung von Survivin in der Abwehr von Chemotherapeutika und deren Formulierungen

Prof. Dr. Roland,
Dr. Désirée

2021 - 2026

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321) (#1349)

Prof. Dr. med. Georg,
Marie-Kristin

2021 - 2040

GISAR - REGISTER (#1316)

Dr. Marius,
Prof. Dr. Thomas,
Sergio

2021 - 2026

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322)

Prof. Dr. med. Georg

2021 - 2040

MORNING (#1317)

Dr. Marius,
Sergio

2021 - 2027

A Phase 1/2a First-in-human Study to Evaluate the Safety, Tolerability and Efficacy of IMA401, a bispecific T cell engaging receptor molecule (TCER®) in patients with recurrent and/or refractory solid tumors.

Marius,
Dr. med. Alexander

2021 - 2027

Pre-Screening for A Phase Ia/Ib first-in-human clinical trial to evaluate the safety, tolerability and Initial anti-tumor activity of IMA401, a bispecific T cell engaging receptor molecule (TCER®), in patients with recurrent and/or refractory solid tumors

Marius,
Dr. med. Alexander

2021 - 2040

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) (#1397)

Dr. Daniel

Starten Sie Ihre Suche...

Johannes Gutenberg-Universität Mainz